Colistin Therapy, Survival and Renal Replacement Therapy in Burn Patients: A 10-Year Single-Center Cohort Study

References

• Zhang P, Zou B, Liou YC, Huang C. The pathogenesis and diagnosis of sepsis post burn injury. Burns Trauma. 2021;9:tkaa047. doi:10.1093/burnst/tkaa047
   PubMed Web of Science ®Google Scholar
• Corcione S, Pensa A, Castiglione A, et al. Epidemiology, prevalence and risk factors for infections in burn patients: results from a regional burn centre’s analysis. J Chemother. 2021;33:62–66. doi:10.1080/1120009X.2020.1780776
   PubMed Web of Science ®Google Scholar
• Papathanakos G, Andrianopoulos I, Papathanasiou A, Priavali E, Koulenti D, Koulouras V. Colistin-resistant Acinetobacter baumannii bacteremia: a serious threat for critically ill patients. Microorganism. 2020;8:287. doi:10.3390/microorganisms8020287
   PubMed Web of Science ®Google Scholar
• Munier AL, Biard L, Legrand M, et al. Incidence, risk factors and outcome of multi-drug resistant Acinetobacter Baumannii nosocomial infections during an outbreak in a burn unit. Int J Infect Dis. 2019;79:179–184. doi:10.1016/j.ijid.2018.11.371
   PubMed Web of Science ®Google Scholar
• Corcione S, Baietto L, Malvasio V, et al. Pharmacokinetics of colistin methanesulfonate (CMS) in burn patients. J Antimicrob Chemother. 2017;72:319–321. doi:10.1093/jac/dkw361
   PubMed Web of Science ®Google Scholar
• Lima WG, Alves GCS, Sanches C, Fernandes SOA, de Paiva MC. Carbapenem-resistant Acinetobacter baumannii in patients with burn injury: a systematic review and meta-analysis. Burns. 2019;45:1495–1508. doi:10.1016/j.burns.2019.07.006
   PubMed Web of Science ®Google Scholar
• Albrecht MC, Griffith ME, Murray CK, et al. Impact of Acinetobacter infection on the mortality of burn patients. J Am Coll Surg. 2006;203:546–550. doi:10.1016/j.jamcollsurg.2006.06.013
   PubMed Web of Science ®Google Scholar
• Giacobbe DR, Saffioti C, Losito AR, et al. Use of colistin in adult patients: a cross-sectional study. J Glob Antimicrob Resist. 2020;20:43–49. doi:10.1016/j.jgar.2019.06.009
   PubMed Web of Science ®Google Scholar
• Butler DA, Biagi M, Tan X, Qasmieh S, Bulman ZP, Wenzler E. Multidrug resistant Acinetobacter baumannii: resistance by any other name would still be hard to treat. Curr Infect Dis Rep. 2019;21:46. doi:10.1007/s11908-019-0706-5
   PubMed Web of Science ®Google Scholar
• Garonzik SM, Li J, Thamlikitkul V, et al. Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients. Antimicrob Agents Chemother. 2011;55:3284–3294. doi:10.1128/AAC.01733-10
   PubMed Web of Science ®Google Scholar
• Gibson GA, Bauer SR, Neuner EA, Bass SN, Lam SW. Influence of colistin dose on global cure in patients with bacteriemia due to carbapenem-resistant gram-negative bacilli. Antimicrob Agents Chemother. 2015;60:431–436. doi:10.1128/AAC.01414-15
   PubMed Web of Science ®Google Scholar
• Wilkinson RE, Hill DM, Hickerson WL. Outcome analysis of colistin- treated burn center patients. Burns. 2017;43:1244–1249. doi:10.1016/j.burns.2017.03.006
   PubMed Web of Science ®Google Scholar
• Vauchel T, Pirracchio R, Chaussard M, et al. Impact of Acinetobacter baumannii outbreak on kidney events in a burn unit: a targeted machine learning analysis. Am J Infect Control. 2019;47:435–438. doi:10.1016/j.ajic.2018.09.010
   PubMed Web of Science ®Google Scholar
• Palmieri T, Lavrentieva A, Greenhalgh DG. Acute kidney injury in critically burn patients. Risk factors, progression and impact on mortality. Burns. 2010;36:205–211. doi:10.1016/j.burns.2009.08.012
   PubMed Web of Science ®Google Scholar
• Tsuji BT, Pogue JM, Zavascki A, et al. International consensus guidelines for the optimal use of the polymyxins: endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti-infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP). Pharmacotherapy. 2019;39:10–39. doi:10.1002/phar.2209
   PubMed Web of Science ®Google Scholar
• Tsuji BT, Pogue JM, Zavascki AP, et al. Polymyxin acute kidney injury: dosing and other strategies to reduce toxicity. Antibiotics. 2019;8(1):24. doi:10.3390/antibiotics8010024
   Web of Science ®Google Scholar
• Katip W, Uitrakul S, Oberdorfer P. Short-course versus long-course colistin for treatment of carbapenem-resistant A. baumannii in cancer patient. Antibiotics. 2021;10(5):484. doi:10.3390/antibiotics10050484
   Web of Science ®Google Scholar
• Katip W, Oberdorfer P. Clinical efficacy and nephrotoxicity of colistin alone versus colistin plus vancomycin in critically ill patients infected with carbapenem-resistant Acinetobacter baumannii: a propensity score-matched analysis. Pharmaceutics. 2021;13:162. doi:10.3390/pharmaceutics13020162
   PubMed Web of Science ®Google Scholar
• Ostermann M, Bellomo R, Burdmann EA, et al. Conference participants. Controversies in acute kidney injury: conclusions from a Kidney Disease: improving Global Outcomes (KDIGO) conference. Kidney Int. 2020;98:294–309. doi:10.1016/j.kint.2020.04.020
   PubMed Web of Science ®Google Scholar
• Fiaccadori E, Pistolesi V, Mariano F, et al. Regional citrate anticoagulation for renal replacement therapies in patients with acute kidney injury: a position statement of the Work Group “Renal Replacement Therapies in Critically Ill Patients” of the Italian Society of Nephrology. J Nephrol. 2015;28:151–164. doi:10.1007/s40620-014-0160-2
   PubMed Web of Science ®Google Scholar
• Mariano F, Leporati M, Carignano P, Stella M, Vincenti M, Biancone L. Efficient removal of colistin A and B in critically ill patients undergoing CVVHDF and sorbent technologies. J Nephrol. 2015;28:623–631. doi:10.1007/s40620-014-0143-3
   PubMed Web of Science ®Google Scholar
• Honore PM, Jacobs R, Lochy S, et al. Acute respiratory muscle weakness and apnea in a critically ill patient induced by colistin neurotoxicity: key potential role of hemoadsorption elimination during continuous venovenous hemofiltration. Int J Nephrol Renovasc Dis. 2013;6:107–111. doi:10.2147/IJNRD.S42791
   PubMedGoogle Scholar
• Leporati M, Bua RO, Mariano F, et al. Determination by LC-MS/MS of colistins A and B in plasma and ultrafiltrate from critically ill patients undergoing continuous venovenous hemodiafiltration. Ther Drug Monit. 2014;36:182–191. doi:10.1097/FTD.0b013e3182a8997c
   PubMed Web of Science ®Google Scholar
• Mariano F, Hollo’ Z, Depetris N, et al. Coupled-plasma filtration and adsorption for severe burn patients with septic shock and acute kidney injury treated with renal replacement therapy. Burns. 2020;46:190–198. doi:10.1016/j.burns.2019.05.017
   PubMed Web of Science ®Google Scholar
• EUCAST. European Committee on Antimicrobial Susceptibility Testing breakpoint tables for interpretation of MICs and zone diameters. Version 7.1; 2017. Available from: http://www.eucast.org/clinical_breakpoints/. Accessed December 31, 2021.
   Google Scholar
• Morris S, Cerceo E. Trends, epidemiology, and management of multi-drug resistant gram-negative bacterial infections in the hospitalized setting. Antibiotics. 2020;9:196. doi:10.3390/antibiotics9040196
   Web of Science ®Google Scholar
• Alp E, Coruh A, Gunay GK, Yontar Y, Doganay M. Risk factors for nosocomial infection and mortality in burn patients: 10 years of experience at a university hospital. J Burn Care Res. 2012;33:379–385. doi:10.1097/BCR.0b013e318234966c
   PubMed Web of Science ®Google Scholar
• Paramythiotou E, Routsi C. Association between infections caused by multidrug-resistant gram-negative bacteria and mortality in critically ill patients. World J Crit Care Med. 2016;5:111–120. doi:10.5492/wjccm.v5.i2.111
   PubMedGoogle Scholar
• Strassle PD, Williams FN, Napravnik S, et al. Improved survival of patients with extensive burns: trends in patients characteristics and mortality among burn patients in a tertiary care burn facility, 2004–2013. J Burn Care Res. 2017;38:187–193. doi:10.1097/BCR.0000000000000456
   PubMed Web of Science ®Google Scholar
• Mariano F, De Biase C, Hollo Z, et al. Long-term preservation of renal function in septic shock burn patients requiring renal replacement therapy for acute kidney injury. J Clin Med. 2021;10(24):5760. doi:10.3390/jcm10245760
   PubMed Web of Science ®Google Scholar
• Christofides C, Moore R, Nel M. Baux score as a predictor of mortality at the CHBAH adult burns unit. J Surg Res. 2020;251:53–62. doi:10.1016/j.jss.2020.01.018
   PubMed Web of Science ®Google Scholar
• Goei H, van Baar ME, Dokter J, et al. Burns in the elderly: a nationwide study on management and clinical outcomes. Burns Trauma. 2020;8:tkaa027. doi:10.1093/burnst/tkaa027
   PubMed Web of Science ®Google Scholar
• Wagenlehner F, Lucenteforte E, Pea F, et al. Systematic review on estimated rates of nephrotoxicity and neurotoxicity in patients treated with polymyxins. Clin Microbiol Infect. 2021;27:671–676.
   Web of Science ®Google Scholar
• Ordooei Javan A, Shokouhi S, Sahraei Z. A review on colistin nephrotoxicity. Eur J Clin Pharmacol. 2015;71:801–810. doi:10.1007/s00228-015-1865-4
   PubMed Web of Science ®Google Scholar
• Dokter J, Meijs J, Oen IM, van Baar ME, van der Vlies CH, Boxma H. External validation of the revised Baux score for the prediction of mortality in patients with acute burn injury. J Trauma Acute Care Surg. 2014;76:840–845. doi:10.1097/TA.0000000000000124
   PubMed Web of Science ®Google Scholar
• Gunay E, Kaya S, Baysal B, Yuksel E, Arac E. Evaluation of prognosis and nephrotoxicity in patients treated with colistin in intensive care unit. Ren Fail. 2020;42:704–709. doi:10.1080/0886022X.2020.1795878
   PubMed Web of Science ®Google Scholar
• Ganapathy H, Pal SK, Teare L, Dziewulski P. Use of colistin in treating multi-resistant Gram-negative organism in a specialised burns unit. Burns. 2010;36:522–527. doi:10.1016/j.burns.2009.07.010
   PubMed Web of Science ®Google Scholar
• Joannidis M, Druml V, Forni LG, et al. Prevention of acute kidney injury and protection of renal function in the intensive care unit: update 2017: expert opinion of the Working Group on Prevention, AKI section, European Society of Intensive Care Medicine. Intensive Care Med. 2017;43:730–749. doi:10.1007/s00134-017-4832-y
   PubMed Web of Science ®Google Scholar
• Wu G, Xiao Y, Wang C, et al. Risk factors for acute kidney injury in patients with burn injury: a meta-analysis and systematic review. J Burn Care Res. 2017;38:271–282. doi:10.1097/BCR.0000000000000438
   PubMed Web of Science ®Google Scholar
• Lee YJ, Wi YM, Kwon YJ, Kim SR, Chang SH, Cho S. Association between colistin dose and development of nephrotoxicity. Crit Care Med. 2015;43:1187–1193. doi:10.1097/CCM.0000000000000931
   PubMed Web of Science ®Google Scholar
• Miano TA, Lautenbach E, Wilson FP, Guo W, Borovskiy Y, Hennessy S. Attributable risk and time course of colistin-associated acute kidney injury. Clin J Am Soc Nephrol. 2018;13:542–550. doi:10.2215/CJN.06980717
   PubMed Web of Science ®Google Scholar
• Chien HT, Lin YC, Sheu CC, Hsieh KP, Chang JS. Is colistin-associated acute kidney injury clinically important in adults? A systematic review and meta-analysis. Int J Antimicrob Agents. 2020;55:105889. doi:10.1016/j.ijantimicag.2020.105889
   PubMed Web of Science ®Google Scholar
• Tsai SY, Lio CF, Shih SC, et al. The predisposing factors of AKI for prophylactic strategies in burn care. Peer J. 2020;8:e9984. doi:10.7717/peerj.9984
   PubMed Web of Science ®Google Scholar